Glutamine With Topical Corticosteroids for Lichen Planus Treatment

Hams Hamed Abdelrahman30 enrolled

Overview

Lichen planus (LP) is an inflammatory skin disease of unknown etiology. Glutamine promotes protein and collagen synthesis, imparts immunity, and maintains the alimentary canal mucosa structure.

Lichen planus (LP) is an inflammatory skin disease of unknown etiology. Recently, increased oxidative stress has been implicated in the pathogenesis of erosive oral lichen planus (EOLP). Glutamine is a source of energy for fibroblasts, immunocompetent cells, and intestinal epithelial cells involved in collagen production. It promotes protein and collagen synthesis, imparts immunity, and maintains the alimentary canal mucosa structure. The aim of this study is to evaluate the effect of Glutamine combined with topical corticosteroid in the treatment of oral erosive LP. Thirty patients with a confirmed clinical and histopathologic diagnosis of OLP recruited in this study and divided into 2 equal groups, each consisting of 15 subjects. Group 1 consists of patients treated with topical steroids plus antifungal (conventional therapy); Group 2 consists of patients treated with Glutamine combined with topical steroids plus antifungal.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Lichen Penis Planus

Interventions

Glutamine Cap/TabDRUG

Glutamine Capsules: One capsule three times daily on an empty stomach for one month

Miconazole Oral gelDRUG

Miconazole oral gel: applied three to four times daily for three weeks

Kenacort in orabaseDRUG

Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached

Eligibility

Sex: ALLMin age: 30 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients clinically and histopathologically diagnosed to be suffering from EOLP. 2. Patients who had symptoms i.e. pain and/or burning sensation secondary to EOLP. 3. Patients under stressful life conditions as evidenced by ISMA-UK Stress Questionnaire 4. Males and Females with an age ranging from 30-60years Exclusion Criteria: 1. Patients suspected to have a lichenoid drug reaction or lichenoid contact allergy. 2. Patients suffering from any systemic diseases (such as diabetes, cardiovascular, liver disorder, renal dysfunction) 3. Patients with findings of any physical or mental abnormality which would interfere with or be affected by the study procedure.

Locations (1)

Outpatient Clinic of Oral medicine Department, Faculty of Dentistry, Alexandria University, Egypt

Alexandria, Egypt

Outcomes

Primary Outcomes

Change in oral lichen planus lesions severity

Mucosal lesion severity score 0: no lesion score 1: white lesion score 2:atrophy/erosion intermixed or not with white lesion score 3: ulceration intermixed or not with white lesion

Time frame: at baseline, 1 months and 3 months

Secondary Outcomes

Change in pain level

Pain score score 0= no pain score 1= mild score 2= moderate score 3= severe

Time frame: at baseline, 1 months and 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.